AJMC® Roundtable: Defining Value for the Treatment of Brain Metastases in HER2+ Metastatic Breast Cancer

AJMC® Roundtable: Defining Value for the Treatment of Brain Metastases in HER2+ Metastatic Breast Cancer

August 16, 2021

This supplement was developed in conjunction with and sponsored by Seagen Inc. The supplement is based upon a roundtable meeting with A. Gajra, W. J. Gradishar, K. Kalinsky, M. Lopes, R. L. Mahtani, S. Soefje, N. Vasan, and R. D. Rao, who received a fee from Seagen Inc. The American Journal of Managed Care® also received a fee from Seagen Inc for providing editorial support.